Rudolf Schlag

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

Jesús F. San Miguel, Rudolf Schlag, Nuriet K. Khuageva et al. · New England Journal of Medicine · 2008 · 1.9K citations · Full text

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

Robert Marcus, Andrew Davies, Kiyoshi Ando et al. · New England Journal of Medicine · 2017 · 764 citations · Full text

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

Barbara Eichhorst, Anna‐Maria Fink, Jasmin Bahlo et al. · The Lancet Oncology · 2016 · 613 citations

Hematological Malignancy, Lymphoid Neoplasia, Oncology +9

Changes in trabecular bone, hematopoiesis and bone marrow vessels in aplastic anemia, primary osteoporosis, and old age: A comparative histomorphometric study

R. Burkhardt, G. Kettner, Wolfgang Böhm et al. · Bone · 1987 · 454 citations · Full text

Primary Osteoporosis, Hematology, Bone Marrow Vessels +6

Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial

María‐Victoria Mateos, Paul G. Richardson, Rudolf Schlag et al. · Journal of Clinical Oncology · 2010 · 431 citations · Full text